| |
Progress in long-acting Agents for HIV Treatment & PrEP:
ViiV healthcare program: Focus on Cabotegravir Long-Acting Injection; Future ViiV LA programs at HIV-DART
|
| |
| |
HIV DART Dec 10 2020
Bill Spreen, PharmD
Cabotegravir Medicine Development leader
ViiV Healthcare
|
|
| |
| |
|
|
|
